BioWorld

Sep. 22, 2004

View Archived Issues

Xenon, Novartis Enter $157M Deal For Obesity Compounds

In a deal that could bring Xenon Pharmaceuticals Inc. $157 million in pre-commercial payments, Novartis Pharma AG agreed to research, develop and commercialize compounds from Xenon's SCD1 drug development program. (BioWorld Today) Read More

'Two Pathways' Now Mapped For Anidulafungin's Approval

Read More

Multitasking Histone Molecule SAHA Affects Kidney Disease

Read More

Coley's Anti-Terrorism TLRs Get Another $16.9M Contract

Read More

Other News To Note

Read More